A Randomized, Double-Blind, Placebo-Controlled Multiple Ascending Dose Study of Intravenous ATYR1923 in Patients with Pulmonary Sarcoidosis

Site Image

Study Overview

This study is being done to learn more about the safety of an investigational drug called ATYR1923, and to find out more about the effects of different doses of this drug on the lungs of people who have pulmonary sarcoidosis. "Investigational" means that it is not approved by the United States Food and Drug Administration. Participants will be assigned at random to receive either the study drug or placebo. A placebo is a harmless inactive substance. The study drug/placebo is given over 60 minutes intravenously (in your vein). Participation will last about 6 months and requires about 12 visits to Penn.

  • Study Identifier: 832623

Recruitment Status


Contact the research team to learn more about this study.

Fields marked with asterisk (*) are required

Please verify that you are not a bot.

By clicking "Contact Research Team", your contact information will be sent securely to the research staff associated with the study. You will also receive a copy of this email in your inbox, as well as other notifications to determine your participation status in the study.

Volunteer Sign up

Volunteer Sign-up

Participate in medical studies to develop new diagnostic and clinical treatments and improve current standards of care.

Sign Up Now!

If you need assistance finding a non-cancer study or if you have any questions, please email psom-ocr@pobox.upenn.edu